Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer

Despite new treatments for castrate-resistant prostate cancer (CRPC), the prognosis of patients with CRPC remains bleak due to acquired resistance to androgen receptor (AR)-directed therapy. The glucocorticoid receptor (GR) and AR share several transcriptional targets, including the anti-apoptotic g...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Horm Cancer
Autores principales: Isikbay, Masis, Otto, Kristen, Kregel, Steven, Kach, Jacob, Cai, Yi, Vander Griend, Donald J., Conzen, Suzanne D., Szmulewitz, Russell Z.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer US 2014
Materias:
Original Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4440041/
https://ncbi.nlm.nih.gov/pubmed/24615402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12672-014-0173-2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares